Nintedanib* has been investigated in lung cancer as part of the LUME-Lung clinical trial program. In this section, you will find an overview of the main trials within this program, as well as links to pages for further information.
Nintedanib clinical trials in NSCLC
The approval of nintedanib for the treatment of adult patients with advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy is based on the pivotal Phase III LUME-Lung 1 trial.1
The following table shows the clinical trials of nintedanib in NSCLC; you can find links to further information on this site and published papers.
Ongoing clinical trials in NSCLC
ADRs, adverse drug reactions; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; SAEs, serious adverse events.
Reck M, et al. Lancet Oncol 2014;15(2):143-55.
ClinicalTrials.gov. NCT02668393. https://clinicaltrials.gov/ct2/show/study/NCT02668393 (Accessed: June 2020).
ClinicalTrials.gov. NCT03017885. https://clinicaltrials.gov/ct2/show/study/NCT03017885 (Accessed: June 2020).
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02671422 (Accessed: June 2020).
Reck M, et al. Poster presented at ESMO 2017 (Poster 1382TiP).
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: August 2020
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue